Fibrinolysis and the contact system: A role for factor XI in the down-regulation of fibrinolysis

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 243-250

  Bouma, Bonno N ^a   Meijers, Joost C M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; FIBRIN; FIBRINOGEN; HIGH MOLECULAR WEIGHT KININOGEN; PREKALLIKREIN; PROTHROMBIN; THROMBIN; THROMBOMODULIN; UROKINASE;

BLEEDING DISORDER; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONFERENCE PAPER; FEEDBACK SYSTEM; FIBRIN FORMATION; FIBRINOLYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; THROMBIN TIME; THROMBOEMBOLISM;

EID: 0032746251     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615839     Document Type: Conference Paper

References (84)

1. Bagdasarian A, Talamo RC, Colman RW. Isolation of high-molecular weight activators of prekallikrein. J Biol Chem. 1973;248:3456-3463.
2. Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med. 1973;138:1564-1583.
3. Griffin JH. The role of surface in the surface-dependent activation of Hageman factor (blood coagulation factor XII ). Proc Natl Acad Sci USA. 1978;75:1998-2002.
4. Tankersley DL, Finlayson JS. Kinetics of activation and autoactivation of human factor XII. Biochemistry. 1984;23:273-279.
5. Wiggins RC, Cochrane CG. The autoactivation of rabbit Hageman factor. J Exp Med. 1979;150:1122-1133.
6. Dunn JT, Silverberg M, Kaplan AP. The cleavage and formation of activated human Hageman factor by autodigestion and by kallikrein. J Biol Chem. 1982;257:1779-1784.
7. Cochrane CG, Revak SD. Dissemination of contact activation in plasma by plasma kallikrein. J Exp Med. 1980;152:608-619.
8. Colman RW, Schmaler AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997;90:3819-3843.
9. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med. 1991;325:153-158.
10. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis. 1991;3:465-468.
11. a in the presence of negatively-charged surfaces. J Biol Chem. 1991;266:7353-7358.
12. Gailani D, Broze GJ. Factor XI activation in a revised model of coagulation. Science. 1991;253:909-912.
13. von dem Borne PAKr, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost. 1994;72:397-402.
14. Cawthern KM, van't Veer C, Lock JB, DiLorenzo ME, Branda RF, Mann KG. Blood: coagulation in hemophilia A and hemophilia C. Blood. 1998;15:4581-4592.
15. Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol. 1999;19:170-177.
16. von dem Borne PAKr, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood. 1995;86:3035-3042.
17. Niewiarowski S, Prou-Wartell O, Rolede facteur contact (Facteur Hageman) dens le fibrinolyse. Thromb Diath Haemorraghica. 1959;3:593-603.
18. Iatridis SG, Ferguson JH. Effect of surface and Hageman factor on the endogenous or spontaneous activation of the fibrinolytic system. Thromb Diath Haemorrhagica. 1961;6:411-423.
19. Saito H, Ratnoff OD, Donaldson VH. Defective activation of clotting, fibrinolytic and permeability enhancing systems in human Fletcher trait plasma. Circ Res. 1974;34:641-651.
20. Saito H, Ratnoff OD, Waldman R, Abraham P. Fitzgerald trait: deficiency of a hitherto unrecognised agent, Fitzgerald factor, participating in surface-mediated reaction of clotting, fibrinolysis, generation of kinins and the property of diluted plasma enhancing vascular permeability (PF/dil). J Clin Invest. 1975;55:1082-1089.
21. Weiss AS, Gallin JI, Kaplan AP. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity and kinin generation. J Clin Invest. 1974;53:622-633.
22. Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest. 1975;56:1663-1672.
23. Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaeras JA, Pierce JV, Kaplan AP, Williams trait: Human Kininogen dificiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman dependent pathways. J Clin Invest 1975;56:1650-1662.
24. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun. 1969;35:273-278.
25. a and urokinase to activate plasminogen. Thromb Res. 1983;9:407-417.
26. Goldsmith GH, Saito H, Ratnoff OD. The activation of plasminogen by Hageman factor (factor XII) and Hageman factor fragments. J Clin Invest. 1978;62:54-60.
27. Mandle RJ Jr, Kaplan AP. Hageman-factor-dependent fibrinolysis: Generation of fibrinolytic activity by the interaction of human factor XII and plasminogen. Blood. 1979;54:850-862.
28. Mandle RJ Jr, Kaplan AP. Human plasma prekallikrein: Mechanism of activation by Hageman factor and participation in Hageman-factor-dependent fibrinolysis. J Biol Chem. 1977;252:6097-6104.
29. Bouma BN, Miles LA, Beretta, Griffin JH. Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by Diisopropyl phosphofluoridate. Biochemistry. 1980;19:1151-1160.
30. Ichinose A, Fujikawa K, Suyama T. The activation of prourokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem. 1986;261:3486-3490.
31. Lenich C, Pannell R, Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost. 1995;74:698-703.
32. Loza JP, Gurewich V, Johnstone M, Pannell R. Platelet bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost. 1994;71:347-352.
33. Gurewich V, Johnstone M, Loza JR, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett. 1993;318:317-321.
34. Motta G, Rojkjaer R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells. Blood. 1998;91:516-528.
35. Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost. 1997;77:522-525.
36. Levi M, Hack CE, de Boer JP, Brandjes DPM, Büller HR, ten Cate JW. Reduction of contact activation related fibrinolytic activity in factor XII-deficient patients: further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest. 1991;88:1155-1160.
37. Lämmle B, Wuillemin WA, Huber I, Krauskopf M, Zurcher R, Pflugshaupt R, Furlan M. Thromboembolism and bleeding tendency in congenital factor XII deficiency: a study on 74 subjects from 14 Swiss families. Thromb Haemost. 1991;65:117-121.
38. Scott CF, Colman RW. Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci USA. 1992;89:11189-11193.
39. Brunnee T, La Porta C, Reddigari SR, Salerno VM, Kaplan AP, Silverberg M. Activation of factor XI in plasma is dependent on factor XII. Blood. 1993;81:580-586.
40. von dem Borne PAKr, Meijers JCM, Bouma BN. Effect of heparin on the activation of factor XI by fibrin bound thrombin. Thromb Haemost. 1996;76:347-353.
41. Gailani D, Broze GJ. Factor XII-independent activation of factor XI in plasma: effects of sulfatides on tissue factor-induced coagulation. Blood. 1993;82:813-819.
42. Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. An empirical study. J Biol Chem. 1994;269:23357-23366.
43. Minnema MC, Pajkrt D, Wuillemin WA, Roem D, Bleeker WK, Levi M, van Deventer SJH, Hack CE, ten Cate H. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood. 1998:92:3294-3301.
44. von dem Borne PAKr, Mosnier LO, Tans G, Meijers JCM, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipids vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost. 1997;78:834-839.
45. Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood - the effect of heparin and aspirin. Thromb Haemost. 1994;72:78-83.
46. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activatable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
47. Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest. 1981;68:1221-1228.
48. Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood. 1986;86:1218-1223.
49. de Fouw NJ, Haverkate F, Bertina RM. Protein C and fibrinolysis: a link between coagulation and fibrinolysis. Adv Exp Med Biol. 1990;281:235-243.
50. Bajzar L, Fredenburgh JC, Nesheim ME. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem. 1990;265:16948-16954.
51. Bajzar L, Nesheim ME. The effect of activated protein C on fibrinolysis in cell free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem. 1993;268:8608-8616.
52. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry. 1995;34:5811-5816.
53. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest. 1995;96:2534-2538.
54. Wang W, Hendriks DF, Scharpé SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem. 1994;269:15937-15944.
55. von dem Borne PAKr, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibition of fibrinolysis. J Clin Invest. 1997;99:2323-2327.
56. Mosnier LO, von dem Borne PAKr, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998:80:829-835.
57. Minnema MC, Friederich PW, Levi M, von dem Borne PAKr, Mosnier LO, Meijers JCM, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998;1:10-14.
58. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem. 1997;272:14477-14482.
59. Weitz JI, Hudoba D, Massel J, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
60. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen on thrombin generation: evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost. 1994;72:713-721.
61. Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Buller HR, ten Cate JW. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation. 1996;93:153-160.
62. Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996;271:16603-16608.
63. Broze GJ, Higuchi DA. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood. 1996;88:3815-3823.
64. Ichinose A. The physiology and biochemistry of factor XIII. In: Haemostasis and Thrombosis. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Edinburgh: Churchill Livingstone; 1994:531-546.
65. Gurewich V, Pannell R. Inactivation single-chain urokinase (prourokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin binding experiments. Blood. 1987;69:769-772.
66. Lijnen HR, van Hoef B, Collen D. Activation of with plasmin of two-chain urokinase type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin. Eur J Biochem. 1987;169:359-364.
67. Braat EAM, Los P, Rijken DC. The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: the effect of thrombomodulin. Blood Coag Fibrinolysis. 1998;9:419-427.
68. Braat EAM, Rijken DC. The inactivation of single-chain urokinase type-plasminogen activator by thrombin may provide an additional explanation for the antifibrinolytic effect of factor XI.Thromb Haemost. 1999;81:657.
69. Bouma BN, von dem Borne PAKr, Meijers JCM. Factor XI and protection of the fibrin clot against lysis - a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost. 1998;80:24-27.
70. Osterud B, Rapaport S. Activation of factor IX by the reaction product of tissue factor and factor VII: an additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA. 1997;74:5260-5264.
71. Marlar RA, Kleiss AJ, Griffin JH. An alternative pathway of human blood coagulation. Blood. 1982;60:1353-1358.
72. Broze GJ. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol. 1992;29:159-169.
73. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered blood. Blood. 1996;88:3422-3445.
74. Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M. Activated protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest. 1998;101:667-676.
75. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-67.
76. Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor V Leiden. J Biol Chem. 1996;271:22949-22952.
77. Griffin JH. Blood coagulation - the thrombin paradox. Nature. 1995;378:337-338.
78. Hanson SR, Griffin JH, Harker LA, Kelly AB, Esmon CT, Gruber A. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest. 1993;92:2003-2012.
79. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood. 1987;70:343-350.
80. Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, Abbink JJ, Strack van Schijndel RJM, Felt-Bersma RJF, Thijs LG, Hack CE. Quantification of plasma factor XII-C1-inhibitor and kallikrein-C1-inhibitior complexes in sepsis. Blood. 1988;72:1841-1848.
81. Pixley RA, de la Cadena R, Page JD, Kaufman N, Wyshock EG, Colman RW, Chang A, Taylor FB. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol. 1992;140:897-906.
82. van der Linden PWG, Hack CE, Eerenberg AJM, Struyvenberg A, van der Zwan JK. Activation of the contact system in insect-sting anaphylaxis: association with the development of angioedema and shock. Blood. 1993;82:1732-1739.
83. Abbink JJ, Kamp AM, Nuijens JH, Eerenberg AJM, Swaak AJF, Hack CE. Relative contribution of contact and complement activation to inflammatory reactions in arthritis joints. Ann Rheum Dis. 1992;51:123-128.
84. Colman RW. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest. 1984;73:1249-1253.